secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001104659-22-056481
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport reports Q1 revenue of $52.3M, net loss $15.4M; FY2022 revenue guidance $260-265M
--------------------------------------------------------------------------------

- Revenue $52.3M, down 2% YoY; net loss to common holders $15.4M ($0.31 loss per share) vs loss of $5.7M ($0.13) in Q1 2021.
- Adjusted EBITDA $1.8M vs $7.2M in prior year; gross margin 42.7% vs 46.1%, impacted by $9.4M fire loss at New Prague plant.
- Biopharma/Pharma revenue $43.0M (+1%); Animal Health $6.8M (-24%); Reproductive Medicine $2.5M (+32%). Commercial therapy revenue grew 53.5% to $3.9M.
- Full-year 2022 revenue guidance $260-265M (17-19% growth). Cash and short-term investments $600M.
- Record 609 clinical trials supported, 81 in Phase 3 (up from 69). Board authorized $100M share repurchase; 306,300 shares repurchased for $8.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922056481/0001104659-22-056481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922056481/tm2214645d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-056481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer